Renitec

Renitec

enalapril

Manufacturer:

Merck Sharp & Dohme

Distributor:

Zuellig Pharma

Marketer:

A. Menarini
Concise Prescribing Info
Contents
Enalapril maleate
Indications/Uses
All grades of essential HTN. Renovascular HTN. All degrees of heart failure. Prevention of symptomatic heart failure. Prevention of coronary ischemic events in patients w/ left ventricular dysfunction.
Dosage/Direction for Use
Essential Mild HTN Initially 10 mg daily. Other degrees of HTN Initially 20 mg daily. Maintenance: 20 mg once daily. Max: 40 mg daily. Renovascular HTN Initiate w/ lower starting dose (eg, ≤5 mg) & adjust accordingly to patient's needs. Mild renal impairment (CrCl >30 to <80 mL/min) Initially 5-10 mg daily. Moderate renal impairment (CrCl >10 to ≤30 mL/min) Initially 2.5-5 mg daily. Severe renal impairment (CrCl ≤10 mL/min) Initially 2.5 mg daily on dialysis days, adjusted depending on BP response on nondialysis days. Heart failure/asymptomatic left ventricular dysfunction Initially 2.5 mg administered under close medical supervision to determine initial effect on BP, may be increased gradually to 20 mg in single or 2 divided doses as maintenance over 2-4 wk period.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. History of angioneurotic edema related to previous treatment w/ ACE inhibitor. Hereditary or idiopathic angioedema. Concomitant use w/ aliskiren in patients w/ diabetes. Combination w/ neprilysin inhibitor eg, sacubitril.
Special Precautions
Hypersensitivity. Anaphylactoid reactions during hymenoptera desensitization. Angioneurotic edema. Symptomatic hypotension in vol-depleted patients eg, by diuretic therapy, dietary salt restriction, dialysis, diarrhea or vomiting; patients w/ ischemic heart or cerebrovascular disease, severe heart failure; obstruction in left ventricle outflow. Cough; DM. Hypoglycemia. Major surgery or during anesth. Concomitant use w/ K-sparing diuretics, K supplements, K-containing salt substitutes or drugs that increased serum K. Hemodialysis patients; renal insufficiency; acute renal failure; bilateral renal or solitary kidney artery stenosis. Not recommended during pregnancy. Lactation. Not to be used in childn.
Adverse Reactions
Dizziness, headache. Fatigue, asthenia; hypotension, orthostatic hypotension, syncope, nausea, diarrhoea, muscle cramps, rash, cough.
Drug Interactions
Additive effect w/ other antihypertensive therapy. Development of hyperkalemia w/ K-sparing diuretics, K supplements, K-containing salt substitutes or drugs that increased serum K. Increased blood glucose-lowering effect w/ antidiabetic drugs. Reduced lithium clearance. Attenuated antihypertensive effect by NSAIDs including selective COX-2 inhibitors. Increased risk of hypotension, syncope, hyperkalemia, renal function changes w/ aliskiren & angioedema w/ mammalian target of rapamycin & neprilysin inhibitors. Nitritoid reactions w/ injectable gold.
ATC Classification
C09AA02 - enalapril ; Belongs to the class of ACE inhibitors. Used in the treatment of cardiovascular disease.
Presentation/Packing
Form
Renitec tab 10 mg
Packing/Price
30's
Form
Renitec tab 5 mg
Packing/Price
30's
Form
Renitec tab 20 mg
Packing/Price
30's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in